此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

GBPDC: Gut-Brain in PD Consortium Master Protocol (GBPDC)

2026年8月20日 更新者：Duke University

Consortium for Gut-Brain Communication in Parkinson's Disease Master Protocol

The purpose of this research study is to identify the role that the gut-brain axis, the group of nerves that connect the brain and gut, plays in Parkinson's disease (PD). The National Institute of Diabetes and Digestive and Kidney Diseases is sponsoring this research study.

During this study, specific groups of participants, also known as "cohorts", will be identified based on the severity of their PD. There will also be a cohort enrolling participants who do not have Parkinson's and a cohort enrolling participants that are at risk for developing PD. Each of these cohorts will be compared to the others to assess the differences in the gut-brain connection.

Participants in this study will:

  • meet with a medical provider
  • answer questionnaires
  • give samples of blood, stool, and saliva
  • have X-rays taken while swallowing different foods (swallowing study)
  • have X-rays taken to see how long it takes markers to move through their colon (colon transit study)
  • have a flexible sigmoidoscopy, where a doctor looks inside the lower part of the colon and takes small tissue samples (biopsies) from the mucosa (lining)
  • have samples taken of their skin
  • have an anorectal manometry and a balloon expulsion test, where a small tube and balloon are placed in the rectum to measure muscle function.

Participation in the study will last up to 24 months (2 years).

研究概览

地位

招聘中

条件

详细说明

The objectives of the master protocol are to establish a common platform that: (1) assures the collection, integration, and analysis of a set of uniformly collected data across all participating centers, and (2) follows the objective of the Gut-Brain Parkinson's Disease Consortium (GBPDC) with the goal "to enhance our understanding of the temporal onset of GI symptoms in PD and changes in gut-brain communication that can be used to leverage the potential role of the GI tract in the pathogenesis and progression of PD and to improve patient diagnosis, care, and outcomes."

Primary Objective

1. To collect prospective cross-sectional and longitudinal participant biospecimens with temporally coordinated evaluations of GI and neurological symptoms and functions to better characterize the phenotype of people with PD versus those without.

Secondary Objectives

  1. To elucidate the biological processes and pathways relevant to the role of the GI tract in the pathogenesis and progression of PD.
  2. To characterize GI symptoms, pathology, and gut-brain communication in PD to detect early and longitudinal changes in gut function and activity that correspond to the development or progression of PD.

Exploratory Objectives

  1. To identify possible novel gut-based biomarkers (functional, molecular, etc.), diagnostic tools, and therapeutic targets.
  2. To investigate the impact of neuroimmune interactions and other pathways in the GI tract on gut-brain communication and PD risk.

In conjunction with clinical, social, and environmental characterization, biospecimen collection within the GBPDC master protocol will provide the opportunity to probe and characterize the pathophysiologic underpinnings of the gut-brain axis in PD, refine existing biomarker testing for PD, and identify new biomarkers that could allow early detection of PD or new targets for treatment.

Duke University will serve as the biorepository for the GBPDC. Participants and study site personnel will collect, process, and ship biospecimens according to the GBPDC Biorepository Manual of Procedures using standard kits assembled specifically for the GBPDC master protocol. Biospecimens will be shipped from the study sites to the GBPDC central biorepository at Duke University for accessioning, storage, tracking, and subsequent distribution for use in approved future research. Throughout the conduct of the master protocol, a portion of the biospecimens received by the GBPDC central biorepository will be transferred to the NIDDK biorepository for approved research use. Any biospecimen aliquots remaining at the GBPDC central biorepository at the termination of the GBPDC program will be transferred to the NIDDK biorepository.

Statistical Design This is a prospective, observational, longitudinal cohort study designed to characterize gut-brain communication in Parkinson's Disease. The study employs a longitudinal design, including cross-sectional analyses of baseline data, to evaluate gastrointestinal and neurological functions in participants with PD compared to household controls and a prodromal cohort, as well as comparisons among PD severity subgroups.

Study Design Features:

  • Multi-center observational study across 5 GNRCs
  • Three participant cohorts: people with PD, people with prodromal features of PD, and household controls. The PD cohort will be further classified as mild, moderate, or severe PD.
  • Longitudinal design with assessments at baseline, 6, 12, 18, and 24 months
  • Comprehensive biospecimen collection coordinated with clinical assessments
  • Household control design where controls are matched to people with PD when available

研究类型

观察性的

注册 (估计的)

250

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 美国
    • California
      • Stanford、California、美国、94305
        • 招聘中
        • Stanford University
        • 接触：
        • 首席研究员：
          • Kathleen L Poston, MD, MS
        • 首席研究员：
          • Laren S Beckers, MD
    • Illinois
      • Chicago、Illinois、美国、60637
        • 尚未招聘
        • University of Chicago
        • 首席研究员：
          • Tao Xie, MD, PhD
        • 首席研究员：
          • Eugene Chang, MD
        • 接触：
      • Chicago、Illinois、美国、60612
        • 招聘中
        • Rush University
        • 首席研究员：
          • Ali Keshavarzian, MD
        • 接触：
        • 首席研究员：
          • Christopher Goetz, MD
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • 尚未招聘
        • Massachusetts General Hospital
        • 接触：
        • 首席研究员：
          • Aleksander Videnovic, MD
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • 招聘中
        • Mayo Clinic
        • 首席研究员：
          • Adil Bharucha, MBBS, MD
        • 接触：
        • 首席研究员：
          • Rodolfo Savica, MD, PhD
    • New York
      • New York、New York、美国、10027
        • 尚未招聘
        • Columbia University
        • 首席研究员：
          • Braden Kuo, MD
        • 接触：
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • 尚未招聘
        • Medical University of South Carolina
        • 接触：

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

取样方法

非概率样本

研究人群

Patients at the NIDDK designated Gastroenterology Neurology Research Centers

描述

Inclusion Criteria (All PD Cohorts)

  1. Aged ≥21 years old and ≤80 years old
  2. Clinical diagnosis of PD as defined by Movement Disorder Society (MDS) PD Criteria
  3. Adequate visual, hearing, cognitive, and physical ability
  4. Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures. Because longitudinal participation is important to the scientific goals of the program, a "best estimate" of interest, commitment, and geographic feasibility for three years will be documented by the enrolling investigator after interview with the potential enrollee

Inclusion Criteria Controls

  1. Aged ≥21 years old and ≤80 years old
  2. No known or diagnosed neurodegenerative disease
  3. Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures
  4. Resides within the same household as person with PD

Inclusion Criteria Prodromal Cohort

  1. Aged ≥21 years old and ≤80 years old
  2. Prodromal characteristics are defined by the MDS Research Criteria for PD and include either polysomnography (PSG)-confirmed rapid eye movement sleep behavior disorder (RBD) or possible RBD (questionnaire-based), with hyposmia as defined by the University of Pennsylvania Smell Identification Test (UPSIT) ≤ 15th percentile.

Exclusion Criteria (All Cohorts)

  1. Diagnosis of secondary or atypical parkinsonism

  2. Laboratory Values:

    1. Hemoglobin (Hgb) <10
    2. Platelets <70,000
    3. Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) > 2 1/2 times upper limit of normal (ULN)
    4. Moderate or severe renal disease with an estimated glomerular filtration rate (eGFR) <60 mL/min/BSA [body surface area]) calculated using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation, or moderate or severe hepatic impairment (alkaline phosphatase [ALP] >2.0 times the ULN and/or total bilirubin >2.0 times the ULN)
    5. Significantly above the normal range for PT/INR/PTT
  3. Currently taking anticoagulants that are deemed exclusionary by the investigator for risk of bleeding with sigmoidoscopy procedure
  4. Clinically significant cognitive impairment with a Montreal Cognitive Assessment (MOCA) score <22
  5. Clinical or laboratory findings consistent with another primary neurodegenerative disease or cognitive disorder other than PD, including but not limited to, frontotemporal lobar disease, Huntington's disease, progressive supranuclear palsy, multisystem atrophy, Creutzfeld-Jakob- Disease, Down's syndrome, cortico-basal degeneration, dementia with Lewy Bodies, Alzheimer's disease, amyotrophic lateral sclerosis, seizure disorder, stroke, or other infectious, metabolic, or systemic disease affecting the central nervous system including, but not limited to, syphilis, present hypothyroidism, present or unaddressed/treated vitamin B12 deficiency, or other screening laboratory abnormalities
  6. Suicidality, defined as active suicidal thoughts or ideation within 6 months before Screening or at Baseline, defined as answering yes to items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS), or history of suicide attempt in previous 2 years, or, in the Investigator's opinion, at serious risk of suicide
  7. Has cancer or has had a malignant tumor within the past 5 years. (Participants with stable untreated prostate cancer or treated/removed cutaneous carcinomas are not excluded.)
  8. Any medical condition or systemic disease that, in the Investigator's opinion, may either put the participant at risk because of participation in the study, influence the results or proposed analyses, or impair the participant's ability to fully participate in the study
  9. Body mass index (BMI) >35 kg/m2 or body weight <50 kg
  10. Participant is currently pregnant, breastfeeding, and/or lactating
  11. History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria)
  12. History of Covid 19 (SARS-CoV-2) infection within 6 weeks prior to screening.
  13. Participants with unresolved symptoms of Covid 19 infection or ongoing cognitive or other deficits attributable to post-Covid 19 that may affect participant safety or interfere with cognitive assessments based on the Investigator's clinical judgment
  14. Either ongoing or current participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken. Participation in other research studies (e.g., observational studies) may be acceptable throughout this study.
  15. History of GI surgery. (However, patients with appendicectomy, hemorrhoid surgery, and cholecystectomy will be eligible to participate).
  16. Regular use of medication that impacts the intestinal barrier (e.g., NSAID more than 3 times weekly)
  17. Has a history of Crohn's disease, ulcerative colitis, and/or other types of colitis (microscopic, lymphocytic, or collagenous colitis). Confirmed diagnosis of inflammatory bowel disease (IBD) and/or, active or uncontrolled IBD symptoms such as diarrhea, bleeding, or severe stomach pain. Treatment for IBD in the past 6 months with medicines such as steroids, biologics, or strong immune-suppressing drugs. Surgery to remove part of the bowel due to IBD. Other long-term gut diseases that cause inflammation, such as celiac disease.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

队列和干预

团体/队列
Household Controls
Age-similar household controls. Household control design where controls are matched to people with PD when available.
People with Parkinson's disease
The Parkinson's Disease (PD) cohort will be further classified as mild, moderate, or severe PD as classified by Hoehn and Yahr scale.
Prodromal Parkinson's disease
People with Parkinson's Disease prodromal features. Prodromal characteristics are defined by the MDS Research Criteria for PD and include either polysomnography (PSG)-confirmed rapid eye movement sleep behavior disorder (RBD) or possible RBD (questionnaire-based), with hyposmia as defined by the University of Pennsylvania Smell Identification Test (UPSIT) ≤ 15th percentile.

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
GI influences on PD
大体时间：enrollment to end of observation at 24 months
Trait and State cross-sectional evaluation of GI influences on PD
enrollment to end of observation at 24 months
Co-associations components of the GBA
大体时间：enrollment to end of observation at 24 months
Cross-sectional co-associations components of the GBA
enrollment to end of observation at 24 months

其他结果措施

结果测量
措施说明
大体时间
GBA Disruption and Parkinson's disease Progression
大体时间：enrollment to end of observation at 24 months
GBA disruption triggered by microbiota dysbiosis (or another GI component of the GBA) predicts PD progression (both motor and non-motor dysfunction/symptoms including GI over time).
enrollment to end of observation at 24 months
GBA Disruption and Prodromal Participants
大体时间：enrollment to end of observation at 24 months
Degree of the "type" or "nature" or "form" of the GBA disruption predict development of PD in prodromal participants over time.
enrollment to end of observation at 24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Duke University

合作者

Medical University of South Carolina
Massachusetts General Hospital
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
University of Chicago
Columbia University
Rush University Medical Center
Stanford University

调查人员

  • 首席研究员：Lisa Wruck、Duke Clinical Research Institute

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年7月3日

初级完成 (估计的)

2028年12月31日

研究完成 (估计的)

2028年12月31日

研究注册日期

首次提交

2026年4月29日

首先提交符合 QC 标准的

2026年4月29日

首次发布 (实际的)

2026年5月5日

研究记录更新

最后更新发布 (实际的)

2026年8月21日

上次提交的符合 QC 标准的更新

2026年8月20日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • Pro00115811
  • 5U24DK140918-02 (美国 NIH 拨款/合同)
  • 5U01DK140933-02 (美国 NIH 拨款/合同)
  • 5U01DK140923-02 (美国 NIH 拨款/合同)
  • 5U01DK140921-02 (美国 NIH 拨款/合同)
  • 5U01DK140936-02 (美国 NIH 拨款/合同)
  • 5U01DK140939-02 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

是的

IPD 计划说明

All IPD related to the GBPDC will be shared via requests submitted through the NIDDK Central Repository.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅